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ABSTRACT
OBJECTIVE: To estimate the prevalence of the contraindicated use of oral contraceptives and 
the associated factors in Brazilian women. 
METHODS: 20,454 women who answered the VIGITEL survey in 2008 also participated in this 
study, of which 3,985 reported using oral contraceptives. We defined the following conditions 
for the contraindicated use of contraceptives: hypertension; cardiovascular diseases such as 
heart attack, stroke/cerebrovascular accident; diabetes mellitus; being smoker and 35 years old 
or older. We estimated the prevalence and 95% confidence intervals of contraindicated use in 
users of oral contraceptives and the factors associated with contraindication by prevalence ratio 
and 95% confidence intervals. 
RESULTS: In the total population, 21% (95%CI 19.7–21.9) of women showed some contraindication 
to the use of oral contraceptives, of which 11.7% (95%CI 10.6–13.7) belonged to the group of 
users of oral contraceptives. The most frequent contraindication in users of oral contraceptives 
was hypertension (9.1%). The largest proportion of women with at least one contraindication 
was aged between 45 and 49 years (45.8%) and with education level between zero and eight 
years (23.8%). The prevalence of contraindication to oral contraceptives was higher in women 
less educated (zero to eight years of study) (PR = 2.46; 95%CI 1.57–3.86; p < 0.05) and with age 
between 35-44 years (PR = 4.00; 95%CI 2.34–6.83) and 45-49 years (PR = 5.59; 95%CI 2.90–10.75). 
CONCLUSIONS: Age greater than or equal to 35 and low education level were demographic 
and iniquity factors, respectively, in the contraindicated use of oral contraceptives.
DESCRIPTORS: Contraceptives, Oral, contraindications. Prescription Drug Misuse. Risk Factors. 
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INTRODUCTION
About 60% of women in reproductive age use some contraceptive method1. This prevalence 
reaches about 70% in Brazil, and oral contraceptive pills (OCP) and female sterilization are 
the most common methods (23.0%)a. 
The OCP, when used correctly and continuously, give the woman effective and safe control 
of her fertility11,21. On the other hand, an online survey conducted in eight countries showed 
discontinuation rate of use of the method of 81%, mostly due to the adverse effects of the 
medicine (57%)8. The same study noted forgetfulness (65%) and intake in wrong time (67%) 
as frequent problems between users of the pills in the Country. 
Even before the many benefits that this method can offer, such as regularization of the 
menstrual cycle and prevention of some types of cancer12, the use of OCP along with some 
conditions such as high blood pressure can increase the risk of cerebrovascular accident 
(CVA), acute myocardial infarction (AMI), and other adverse outcomes in women5. Besides 
hypertension, the following conditions contraindicate the use of OCP: diabetes mellitus 
with vascular disease, smoking in women with 35 years old or older, cardiovascular diseases, 
thromboembolism, migraine with aura, among others. In response to this situation, the 
Brazilian Ministry of Health and other international agencies adopted recommendations 
for their useb,c. The eligibility criteria for the use of OCP can be determined by a detailed 
evaluation, with clinical and family history of the woman and blood pressure measurement. 
In some countries, access to the method is subject to previous evaluation. In the United 
States, in addition to the contraindications being infrequent in women in reproductive age, 
the prevalence of use along with contraindication is approximately 5%5,18,21. 
One way to acquire or start the use of OCP in Brazil is by consultation with health professional 
in public or private health services. Another possibility is the acquisition of the drug in 
drugstores without mandatory prescription. 
Due to the widespread use of OCP without prescription, the ignorance of the contraindicated 
use is very likely. This can lead to adverse health effects. A recent study assessed the knowledge 
of women on the effects of OCP on their health in five Brazilian cities and showed that users 
know little about the contraceptive method they are using11. 
There are no Brazilian population surveys to assess the extent of this problem. A few studies 
show concern in assessing the presence of contraindications to the use of the pill among 
women5,18,21,22. This is relatively expected in Brazil, since most women is not under the control 
of health services, acquiring the pill directly from drugstores. 
Knowing the trends of use of contraceptive methods and their associated factors, as well 
as the characteristics of women using the method, can contribute to the planning and 
adaptation of public policies and to better access and use by the population. 
This study aimed to estimate the prevalence of contraindicated use of OCP in Brazilian 
women. Our hypothesis is that there are differences in prevalence of contraindicated use of 
OCP according to sociodemographic variables in Brazilian women.
METHODS
This study used the rotating module of questions related to the use of contraceptive 
methods answered by women who participated in the system of Vigilância de Fatores de 
Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (VIGITEL) in 2008. It is 
composed of probabilistic samples of the adult population living in households with at 
least one fixed telephone line in the current year in the capitals of the 26 Brazilian States 
and in the Brazilian Federal District13. 
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The questionnaire included questions about feeding, physical activity, smoking, 
alcohol consumption, self-reported morbidity, weight, and height, health situation, 
and sociodemographic variables. In 2008, rotating modules were incorporated in the 
questionnaire: possession of health insurance, access to mental health services, and use of 
contraceptive methods. The following questions were included: “Currently, do you use any 
method to prevent pregnancy?” (yes/no); “Which method do you use more frequently?” 
(tubal ligation, condom, injection, pill, hormonal implant, IUD, diaphragm, vasectomy – for 
men only –, others). 
The VIGITEL interviewed 54,353 individuals in 2008, of which 32,918 were women. Of these, 
21,074 had reproductive age (15 to 49 years) and constituted the population of this study (Figure).
Exclusion criteria were: women who reported being pregnant at the time of interview (n = 457) 
or who did not know (n = 112); and women who have not responded any alternative of the 
covariates of interest, such as having access to health insurance (n = 28) and skin color 
(n = 21), totaling 20,454 women. Of these, 34% reported not carrying out family planning 
or using any contraceptive method. Compared to those who reported using some method, 
23.2% reported use of oral contraceptives (Figure). 
The dependent variables were constructed using the definition of contraindication to the 
use of oral contraceptives published in 2010 by the World Health Organization (WHO) and 
adopted by the Brazilian Ministry of Health (MS)c, as well as the more recent recommendation 
of the Centers for Disease Control in the United Statesb. We considered the following 
conditions for the contraindicated use of contraceptives: hypertension (SH) (yes/no); 
cardiovascular diseases (CVD) such as heart attack and stroke/CVA (cerebrovascular 
accident) (yes/no); diabetes mellitus (yes/no); being smoker and over 35 years old at the 
same time (yes/no). The occurrence of at least one of these conditions was considered a 
contraindication to the use of OCP.
OCP: oral contraceptive pills 
a sample n.
b population estimate. 
c intrauterine device and diaphragm.
Figure. Flowchart of the population available for study. VIGITEL, Brazil, 2008.
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The independent variables used were: age (18 to 24, 25 to 34, 35 to 44, 45 to 49 years), education level 
(zero to eight, nine to 11, 12 or more years of study), skin color (white, black, brown, and others), 
marital status (single, married or in stable union, widow, divorced), health plan or insurance 
(yes/no), housing region (North, Northeast, South, Southeast, and Midwest), all self-reported.
We conducted a non-conditional analysis based on the definition of subpopulation of 
interest19. Missing data and subgroups that met exclusion criteria were included in the 
category 0 of the variable indicating subpopulation, and the studied population was included 
in category 1. This method is more suitable to estimate the variance for representative samples 
of large populations. We estimated the prevalence and 95% confidence intervals (95%CI) 
of the contraindications for all population and according to the use of contraceptives. For 
women who reported using OCP, we estimated the proportions and non adjusted prevalence 
ratios (PR) and 95%CI of the use of OCP along with at least one contraindication, according 
to sociodemographic characteristics, using Poisson regression. Statistical differences between 
the proportions were evaluated by Pearson’s Chi-squared test. We estimated the adjusted 
PR and 95%CI. We used Wald’s Chi-squared test to assess the statistical significance of the 
contribution of each variable in the multivariate model. A significance level of p < 0.05 was 
used to reject the null hypothesis in all tests.
We used the statistical program Stata, version 12.0, and the commands of the survey module, 
considering the weights and representativeness of the sample. 
The VIGITEL was approved by the National Research Ethics Committee for Human Beings of 
the Ministry of Health under Opinion 749/2006, according to the principles of the Declaration 
of Helsinki. As the data were obtained by telephone interview, the informed consent form 
was replaced by verbal consent, obtained during the telephone contacts with respondents. 
The researchers did not have access to the identity of participants.
RESULTS
Of 20,454 women, about 21.0% showed at least one potential contraindication to use OCP, 
with 11.7% of them in the group of users and 23.5% in the group of non-users (Table 1). 
Among OCP users, 10.5% presented one contraindication and 1.2%, two contraindication 
conditions (Table 1). The most frequent contraindication was systemic hypertension (SH) 
(15.1%). The habit of smoking in women aged 35 years or older was the second most frequent 
contraindication (2.6%) (Table 1). 
Table 1. Prevalence of contraindications to oral contraceptive use among Brazilian women. VIGITEL, Brazil, 2008.
Contraindications
Total women 
(n = 20.454)
Use of OCP
Yes 
(n = 3.985)
No 
(n = 16.469)
n % 95%CI n % 95%CI n % 95%CI
At least one contraindication 4,040 20.8 19.7–21.9 480 11.7 10.6–13.7 3,560 23.5 22.3–24.8
Number of contraindications
1 3,454 17.4 16.4–18.4 426 10.5 8.9–12.4 3,028 19.5 18.4–20.7
2 531 3.1 2.6–3.7 50 1.2 0.8–1.9 481 3.6 3.0–4.3
3 or + 55 0.3 0.1–0.5 4 0.03 0.01–0.1 51 0.4 0.2–0.6
Types of contraindications
SH 2,874 15.1 14.1–16.1 354 9.1 7.6–10.8 2,520 16.9 15.7–18.1
Smokers and ≥ 35 years 1,156 6.1 5.5–6.7 112 2.6 1.8–3.7 1,044 7.1 6.4–8.0
DM 451 2.2 1.8–2.6 51 0.9 0.6–1.4 400 2.6 2.2–3.1
CVD 201 1.1 0.8–1.5 21 0.5 0.3–0.9 180 1.3 0.9–1.8
OCP: oral contraceptive pills; SH: systemic hypertension; DM: diabetes mellitus; CVD: cardiovascular disease
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There was higher prevalence of contraindicated use in women who have low education level 
(zero to eight years of study), when compared with those with more education (PR = 3.76; 
95%CI 2.44–5.80) (Table 2). This prevalence was also high in women aged 45-49 years when 
compared with younger ones (PR = 7.30; 95%CI 4.2–12.8). The contraindicated use of OCP 
was more frequent in separated/divorced women (27.3%), followed by widow women (15%). 
A higher proportion of women presented at least one contraindication among those who 
had health plan or insurance (14.8%) (p < 0.05). The contraindication was more prevalent 
in women classified as other (yellow, red/indigenous, do not know, and would not inform) 
(21%), followed by brown (13.6%) and black women (11.2%). The North region concentrated 
most women with at least one contraindication (14%), followed by South (11.9%) and 
Southeast (11.8%).
The factors that remained associated with contraindications in women using OCP were low 
education level and age ≥ 35 years in the adjusted analysis (Table 3). 
Table 2. Prevalence and 95% confidence intervals of contraindicated use of oral contraceptive among 
users of the method, according to sociodemographic characteristics. VIGITEL, Brazil, 2008. 
Sociodemographic characteristics
Women using OCP
n % 95%CI pa PR 95%CI pb
Education level (years) < 0.0001
12 and more 1,840 6.3 4.4–9.0 1.0 - -
9 to 11 1,670 10.4 8.2–13.0 1.6 1.1–2.5 0.022
0 to 8 475 23.8 18.5–30.0 3.8 2.4–5.8 < 0.000
Age (years) < 0.0001
18 to 24 1,172 6.2 3.4–9.6 1.0 - -
25 to 34 1,858 7.5 5.7–9.7 1.2 0.7–2.0 0.493
35 to 44 823 30.7 25.0–37.0 4.9 3.0–8.0 < 0.000
45 to 49 132 45.8 31.3–61.1 7.3 4.2–12.8 < 0.000
Marital status 0.0001
Single 2,021 8.8 6.8–11.3 1.0 - -
Married 1,802 14.8 12.1–18.1 1.7 1.2–2.3 0.001
Widow 26 15.0 5.3–35.8 1.7 0.6–4.7 0.303
Separated/Divorced 136 27.3 15.7–43.1 3.1 1.8–5.5 < 0.000
Has health plan or insurance 0.003
Yes 2,308 14.8 12.2–17.7 1.0 - -
No 1,677 9.2 7.1–11.9 0.6 0.4–0.8 0.004
Skin color 0.176
White 1,832 9.9 7.7–12.5 1.0 - -
Black 190 11.2 6.6–18.5 1.1 0.6–2.0 0.660
Brown 1,942 13.6 11.0–16.8 1.4 1.0–1.9 0.530
Other 21 21.0 5.0–57.2 2.1 0.6–7.8 0.255
Region 0.844
North 928 14.0 10.3–18.9 1.0 - -
Northeast 979 11.5 8.8–15.0 0.8 0.5–1.3 0.334
Midwest 722 10.7 8.3–13.7 0.8 0.5–1.1 0.179
Southeast 734 11.8 9.0–15.3 0.8 0.6–1.2 0.394
South 632 11.9 9.2–15.2 0.8 0.6–1.2 0.409
OCP: oral contraceptive pills; PR: prevalence ratio
a Pearson’s Chi-squared.
b Wald’s Chi-squared.
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DISCUSSION 
About 20% of Brazilian women showed some condition that contraindicates the use of OCP. 
This proportion was 11.7% in women using OCP. The main condition for contraindicated 
use was SH, followed by age over 35 years along with smoking.
Most studies that measured the magnitude of use of OCP in the presence of contraindication 
were carried out with North American populations5,18,21,22. Data from the National Health and 
Nutrition Examination Survey (NHANES) showed contraindication prevalence of 6% among 
users of OCP in the United States, half of what we found, and 19% among non-users of the 
method18. Another study showed higher prevalence of contraindication among American 
women who buy OCP on drugstores (13%) when compared to those served in clinics (9%)5. 
However, an internet survey showed that 23.7% of North American users of OCP had some 
contraindication condition22. On the other hand, the North American Project CHOICE 
showed that 3% of women used OCP with some contraindication, showing great variability 
in the estimation of this parameter, which could be explained by the different samples and 
contexts of the women accessed in each study. 
Table 3. Prevalence ratios and 95% confidence intervals for the presence of at least one contraindication 
among users of oral contraceptive, according to sociodemographic characteristics. VIGITEL, Brazil, 2008. 
Sociodemographic characteristics
Contraindication
Adjusted PR 95%CI p*
Education level (years)
12 and more 1.0 - -
9 to 11 1.7 1.1-2.5 0.014
0 to 8 2.5 1.6-3.9 < 0.000
Age (years)
18 to 24 1.0 - -
25 to 34 1.1 0.6–1.9 0.727
35 to 44 4.0 2.3–6.8 < 0.000
45 to 49 5.6 2.9–10.7 < 0.000
Marital status
Single 1.0 - -
Married 1.0 0.7-1.4 0.939
Widow 0.6 0.2-1.8 0.354
Separated/Divorced 1.5 0.8-2.8 0.160
Has health plan or insurance
Yes 1.0 - -
No 0.9 0.7–1.2 0.522
Skin color
White 1.0 – -
Black 0.9 0.5–1.7 0.754
Brown 1.1 0.8–1.6 0.450
Other 2.4 0.7–8.6 0.162
Region
North 1.0 - -
Northeast 0.8 0.5–1.2 0.522
Midwest 0.8 0.6–1.2 0.316
Southeast 0.8 0.6–1.3 0.444
South 0.8 0.6–1.2 0.353
PR: Prevalence Ratio
* Wald’s Chi-squared.
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There are no similar population studies using a representative sample population in Brazil. 
A local study, conducted in Pelotas (RS), between 1992 and 1999, showed that, among the 
279 users of OCP, 22.2% presented some contraindication for their consumption. The most 
prevalent condition was smoking in women over 35 years, followed by SH3.
In this study, the prevalence of contraindications to use OCP was similar to that of the 
presented studies. Thus, even if the use of OCP is safe as a measure of fertility control, their 
use along with a contraindication is an indicator of problems in the quality of actions for 
family planning and integrality of health actions. The sharp growth in the use of contraceptive 
methods in Brazil in recent decades reached about 80% of women in reproductive age in 
2006a. Among the methods, the use of OCP is expected to keep growing, since they are the 
second most widely used contraceptive method in Brazil, followed by tubal ligature, often 
associated with the epidemic of Caesarean sections in force since the 90s. One must expect 
a behavior similar to the world trend, in which the OCP method may be the first election. 
Thus, the promotion of proper use is essential, that is, that the method is used by women 
who meet the eligibility criteria. The use along with a contraindication may result in damages 
to health, putting it at risk of more serious events. 
Self-reported SH was the most prevalent contraindication, confirming studies carried out 
with other populations5,21. Women whose blood pressure was not measured before starting 
the use of OCP showed increased risk of acute myocardial infarction (AMI). Therefore, their 
blood pressure must be measure before starting the use of the method20,c. The prolonged 
use of OCP may increase twice the chance of developing hypertension15. This indicates that 
hypertension can be aggravated with the use of OCP, tripling the odds ratio (OR = 2.67) of 
non-control of blood pressure (≥ 140/90 mmHg) when compared to non-users10. On the 
other hand, the suspension of OCP in hypertensive women reduced in 15 mmHg the systolic 
blood pressure and in 10 mmHg the diastolic blood pressure10. In this study, we observed 
higher proportion of contraindicated use among women over 35 years, known to be more 
vulnerable to the occurrence of hypertension and other diseases, more prevalent with age. 
The second most prevalent contraindication was smoking and age ≥ 35 years together. The 
risk of AMI in women who smoke and have less than 35 years is 10 times greater than that 
of those who do not smoke20, and this risk in women older than 35 is higher regardless of 
smoking. Thus, the risk of AMI among these users also increases with the coexistence of 
cardiovascular risk factors, such as smoking, which potentiates this effect on women over 
352,20. The number of cigarettes also affects this evaluation, but this information is not 
available on VIGITEL, 2008. 
The contraindicated use of OCP is also a cardiovascular risk factor, especially in women 
over 30 years old. This is troubling, since the main cause of morbidity and mortality in Brazil 
are the cardiovascular system diseasesd. Facing this problem means preventing risk factors, 
including the contraindicated use of OCP3.
This study showed that women over 34 years, separated/divorced, with private health plan, 
and low education level presented higher prevalence of contraindication to the use of OCP. 
Explanations of these findings as a whole are relatively complex, since they involve factors 
of diverse and sometimes speculative nature, such as access to information and effective 
management of contraception, which involves issues such as the criterion of effectiveness, 
unimpeded sexuality, and female protagonism that the use of the pill represents to many 
womene. In addition, there is reproductive assistance concentrated in women who experience 
the pregnancy-puerperal cycle7, leaving women with extremes of age, as adolescents and 
older women, on the sidelines of the reproductive planning. Self-medication may still be a 
result of individual social and political processes, not necessarily of access to method and 
information4. It can also result from feminine socialization marked by learning with friends, 
from the acquisition of the medicine in drugstores, and from the dependence of this for 
contraceptione. Finally, the pill was reported as an easier method to use and obtain in health 
servicese. However, a regional study showed that neither the indication for use of OCP in 
d Institute for Health Metrics 
and Evaluation (IHME). Global 
Burden of Disease (GBD) 
profile: Brazil. Seattle: IHME; 
2013 [cited 2013 Apr 30). 
Available from: http://www.
healthmetricsandevaluation.org/
gbd/country-profiles
e Cabral CS. Socialização 
contraceptiva e o aprendizado 
da sexualidade: uma abordagem 
socioantropológica do processo 
de construção da prática 
contraceptiva. In: Anais do 
18º Encontro Nacional de 
Estudos Populacionais; 13 
a 23 de Novembro, 2012; 
Águas de Lindóia/SP-Brasil. 
Associação Brasileira de Estudos 
Populacionais; 2012.
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health services nor getting the medicine on the service itself have improved its fitness when 
compared with the acquisition by the user herself6. We were not able to show this result here 
due to the lack of data about the source of recommendation of its use. 
Education level was an iniquity factor to the use of OCP: there was higher prevalence of 
contraindication in women with low educational level. The education level is expected to 
improve the proper choice of OCP. Better educated women used contraceptive methods 
more often. Those with less education had more children than they wanted to, and the most 
prevalent method was tubal ligationd. As is the case in Brazil, in high-income countries, 
the difficulty of choice of appropriate method can be extended to women who did not 
finish higher education22. Women with more education may have greater understanding of 
information about the method they wish to use and the risks inherent in it.
The unequal access to contraception can also be related to increased access to the 
diversity of methods by women with more education. The findings point to the difficulty 
of SUS in achieving greater democratization of access to the wide variety of contraceptive 
methods, as well as to the inefficiency in the supply of reproductive planning assistance 
in primary health-care. 
One of the main limitations of this study is the use of telephone interviews. The coverage of 
fixed telephone lines ranges from 34% to 82% in the capitals in which the samples were drawn. 
However, the system presents response rates above 60%. Because of its convenience and 
relatively low cost, the use of health surveillance systems by telephone survey is an efficient 
and practical methodology to the context of health surveillance. A comparative study between 
researches conducted by face-to-face interviews and telephone survey provides evidence 
in favor of the latter, provided that it is performed with well-structured questionnaires and 
trained interviewers14,17. This limitation can be circumvented with the inclusion of post-
stratification weights of the samples. The use of post-stratification corrections obtained by 
the weights estimated using statistical strategies effectively reduces the risk of systematic 
errors related to fixed telephony coverage. 
Another limitation of this study is the self-reported data, since subclinical events may be 
underestimated. This can be due to ignorance of the health conditions of the individual, as 
a result of many reasons, such as lack of access to health services, lack of consensus among 
doctors about the criteria used to report these conditions to the bearer, individual limitations 
regarding the capacity of understanding of individuals about their own health condition.
Some important contraindications to the use of OCP, such as thromboembolism and migraine 
with aura, were not measured by VIGITEL, 2008. For this reason, the prevalence of use of 
OCP along with contraindication may be underestimated. Data concerning other aspects 
of the reproductive history of women were also not available in this survey. These variables 
can potentially be determinants of the use of contraceptive methods, indicating that the 
final analysis can incorporate residual confusion.
The non-characterization of the type of OCP reported by the user in terms of their hormonal 
composition can be considered another potential limitation. OCP composed only of 
progestogens have contraindications only for more serious diseases. However, the use of 
this type of contraceptive is relatively low, probably because of the side effects, such as 
breakthrough bleeding, present in about 70% of women using this method9,16. Thus, the 
results of estimates of contraindicated use should be faced with caution and regarded as 
epidemiological marker events of their use.
The results of this study estimated a prevalence of almost 12% of use of OCP along with 
contraindications among Brazilian women in reproductive age. Education level was an 
inequity factor in the contraindicated use of OCP, and the group of women over 35 years 
presented itself as a potential surveillance group in their contraindicated use. This study 
may help identifying the possible existence of an undesirable iniquity in the reproductive 
health-care of Brazilian women. 
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The findings of this study point to the need for reviewing the activities and services concerning 
the reproductive planning in the Country, including counseling and free informed choice. 
Even with the availability of OCP in drugstores counters, one must empower women about 
their risks and benefits, as well as of other options for birth control. The identification 
of inequalities in the access and use of health services is focus of attention of academic 
researches and public administrators, for it provides important information to the planning 
of public health actions. Surveillance systems can help monitoring possible trends of the 
outcome studied. 
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